Department of Cell Biology, Institute of Basic Medical Sciences, 27 Tai-Ping Road, Beijing 100850, P.R.China.
In Vivo. 2010 Sep-Oct;24(5):659-66.
Recent data have demonstrated that mesenchymal stem cells (MSCs) have potent immune regulation capacity in vitro, enhancing their therapeutic appeal for their utilisation in the management of acute graft-versus-host disease (aGvHD). However, their immunoregulatory activity in vivo is largely unknown.
Using murine compact bone-derived MSCs in an aGvHD model, the phenotypic status of splenocytes of aGvHD and aGvHD+MSC groups of mice were examined by flow cytometry.
MSC infusion decreased the expression of MHC-II and CD69 molecules on splenic CD11b+ cells of aGvHD mice, which resulted in decreased maturation of antigen-presenting cells. Moreover, the down-regulated ratio of CD3+CD69+ to CD3+ cells, leading to restrained early activation and effector T-cell formation, resulted in the enhancement of the absolute and relative number of splenic CD3+ cells by MSCs co-transfer.
This study demonstrated that MSCs can inhibit the three developmental stages of aGvHD.
最近的数据表明，间充质干细胞（MSCs）在体外具有强大的免疫调节能力，这增加了它们在急性移植物抗宿主病（aGvHD）治疗中的吸引力。然而，其在体内的免疫调节活性在很大程度上是未知的。
本研究使用鼠紧凑骨源性 MSCs 在 aGvHD 模型中，通过流式细胞术检查 aGvHD 和 aGvHD+MSC 组小鼠脾细胞的表型状态。
MSC 输注降低了 aGvHD 小鼠脾 CD11b+细胞上 MHC-II 和 CD69 分子的表达，导致抗原呈递细胞的成熟减少。此外，下调的 CD3+CD69+与 CD3+细胞的比例，导致早期激活和效应 T 细胞形成受到抑制，从而增强了 MSC 共转移对脾 CD3+细胞的绝对和相对数量的增强。
本研究表明，MSCs 可以抑制 aGvHD 的三个发展阶段。
Zotero 插件